Lornoxicam

Sold as Xefo, Xefo iv/im, Xefo rapid, Noxpain, Lornbloc, Noxpain rapid, Lievocam, Lornoxicam zydus

C₁₃H₁₀ClN₃O₄S₂371.80 g/mol

6-Chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide

Drag to rotate. Structure from PubChem CID 54690031.

Loading Wikipedia summary

Registration

Applicants: 3
Registrations: 13
Schedule source: Consolidated Schedules 06 July 2026

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Acino Pharma (Pty) Ltd	Xefo, Xefo iv/im, Xefo rapid, Noxpain, Noxpain rapid	4, 8 mg	330247, 330248, 330249, 440331, 450018, 450019, 560127	S3	PI PIL
Pharmacare limited û woodmead	Lornbloc	4 mg, 8 mg	480735, 480736	S3	None
Zydus Healthcare (Pty) LtdCertificate held by Zydus Healthcare SA (Pty) Ltd	Lievocam, Lornoxicam zydus	4 mg, 8 mg	561150, 561151.1150, 590485, 590486.485	S3	PI PIL

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Xefo 4 EACH TABLET CONTAINS LORNOXICAM 4,0 mg	4	33024733/3.1/0247	Registered	S3	None
Xefo 8 EACH TABLET CONTAINS LORNOXICAM 8,0 mg	8	33024833/3.1/0248	Registered	S3	None
Xefo 8 iv/im EACH VIAL CONTAINS LORNOXICAM 8,0 mg	8 mgWater for injection	33024933/3.1/0249Approved 31 October 2024	Registered	S3	PI PIL
Xefo rapid EACH TABLET CONTAINS LORNOXICAM 8,0 mg	Not listed	44033144/3.1/0331	Registered	S3	None
Noxpain 4 EACH TABLET CONTAINS LORNOXICAM 4,0 mg	4	45001845/3.1/0018	Registered	S3	None
Noxpain 8 EACH TABLET CONTAINS LORNOXICAM 8,0 mg	8	45001945/3.1/0019	Registered	S3	None
Lornbloc 4 MG EACH TABLET CONTAINS LORNOXICAM 4,0 mg	4 mg	48073548/3.1/0735	Registered	S3	None
Lornbloc 8 MG EACH TABLET CONTAINS LORNOXICAM 8,0 mg	8 mg	48073648/3.1/0736	Registered	S3	None
Noxpain rapid EACH TABLET CONTAINS LORNOXICAM 8,0 mg	8 mgTablet	56012756/3.1/0127Approved 10 May 2022	Registered	S3	PI PIL
Lievocam 8 MG EACH TABLET CONTAINS LORNOXICAM 8,0 mg	8 mgFilm-coated tablet	56115056/3.1/1150Approved 30 June 2026	Registered	S3	PI PIL
Lornoxicam 8 MG zydus EACH TABLET CONTAINS LORNOXICAM 8,0 mg	8 mg	561151.115056/3.1/1151.1150	Registered	S3	None
Lievocam 4 MG EACH TABLET CONTAINS: LORNOXICAM 4,0 mg	4 mg	59048559/3.1/0485	Registered	S3	None
Lornoxicam 4 MG zydus EACH TABLET CONTAINS: LORNOXICAM 4,0 mg	8 mgFilm-coated tablet	590486.48559/3.1/0486.485Approved 30 June 2026	Registered	S3	PI PIL

Regulatory status

Where S3 sits on the scale

S0S1S2S3S4S5S6S7S8

Needs a doctor's prescription, dispensed by a pharmacist.

Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S3, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Lornoxicam

S3: Lornoxicam
Consolidated Schedules 06 July 2026, line 3906

Pharmacological class: Antirheumatics (anti-inflammatory agents). (class 3.1)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Professional information (PI)For healthcare professionalsXefo 8 iv/im, Acino Pharma (Pty) Ltd Patient information leaflet (PIL)For patients and carersXefo 8 iv/im, Acino Pharma (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background